Dianthus Therapeutics, Inc.
DNTH
Rangering i aksjer
#4060
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Aksjekurs
$71.45
Sist synkronisert: 2026-10-16
Markedsverdi
$4.00B
Endring (1 dag)
-4.13%
Endring (1 år)
100.42%
Land
US
Handel Dianthus Therapeutics, Inc. (DNTH)
Kategori
Healthcare
EPS for Dianthus Therapeutics, Inc. (DNTH)
EPS per June 2026 TTM: $-0.13
Ifølge de siste økonomiske rapportene og aksjekursen til Dianthus Therapeutics, Inc. er selskapets nåværende EPS (TTM) $-0.13. Ved slutten av 2023 hadde selskapet en EPS på $-8.45, en økning sammenlignet med EPS-en i 2022 som var $-7.60.
EPS-historikk for Dianthus Therapeutics, Inc. fra 2016 til 2026
EPS ved slutten av hvert år
| År | EPS | Endre |
|---|---|---|
| 2026 (TTM) | $-0.13 | -94.90% |
| 2024 | $-2.55 | -69.82% |
| 2023 | $-8.45 | 11.18% |
| 2022 | $-7.60 | 98.95% |
| 2021 | $-3.82 | -86.01% |
| 2020 | $-27.30 | -17.72% |
| 2019 | $-33.18 | 20.13% |
| 2018 | $-27.62 | 72.09% |
| 2017 | $-16.05 | 275.88% |
| 2016 | $-4.27 | 0.00% |
EPS for lignende selskaper eller konkurrenter
| Selskap | EPS | EPS-forskjell | Land |
|---|---|---|---|
| $17.32 | -13,423.08% |
US
|
|
| $-7.98 | 6,038.46% |
US
|
|
| $-5.29 | 3,969.23% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -21,438.46% |
NL
|
